Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy Publisher Pubmed

Balouchi S¹ ; Gharagozloo M^{1, 2} ; Esmaeil N¹ ; Mirmoghtadaei M³ ; Moayedi B¹

Show Affiliations

1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 81744-176, Iran
2. School of Pharmacy, University of Waterloo, ON, Canada
3. School of Medicine, Tehran University of Medical Science, Tehran, Iran

Source: Immunopharmacology and Immunotoxicology Published:2014

Abstract

Several immunological abnormalities have been characterized in β-thalassemia, many of which are linked to or identified with cytokines. In this study, we investigated the serum levels of TGF-β, IL-10, IL-17 and IL-23 in β-thalassemia major patients in comparison with healthy controls. The immunomodulatory effect of silymarin (a flavonoid complex obtained from Silybum marinum) on the serum levels of cytokines was further evaluated in thalassemia patients receiving silymarin (420 mg/day) and compared with patients treated with placebo for 6-month. Serum cytokines levels were measured by enzyme linked immunosorbent assay (ELISA). The results showed a significant higher concentration of TGF-β and IL-23 in the patient group than control group. Among studied cytokines, a significant reduction in serum IL-10 levels was found in patients treated with silymarin when compared with IL-10 values at baseline. However, no significant difference was observed between baseline values of cytokine compared with end values in placebo group. Our data suggest the presence of imbalanced immune condition involving inflammation and immunosuppression in thalassemia patients, which could be modulated to a more effective immune response by silymarin. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.

Related Docs

View other Related Docs

1. Immunomodulatory Effects of Silymarin in Patients With Β-Thalassemia Major, International Immunopharmacology (2013)

2. Double-Faced Cell-Mediated Immunity in Β-Thalassemia Major: Stimulated Phenotype Versus Suppressed Activity, Annals of Hematology (2009)

3. Evaluating the Safety and Efficacy of Silymarin in Β-Thalassemia Patients: A Review, Hemoglobin (2015)

4. A Randomized Double-Blind, Placebo-Controlled Study of Therapeutic Effects of Silymarin in Β-Thalassemia Major Patients Receiving Desferrioxamine, European Journal of Haematology (2013)

5. Combined Therapy of Silymarin and Desferrioxamine in Patients With Β-Thalassemia Major: A Randomized Double-Blind Clinical Trial, Fundamental and Clinical Pharmacology (2009)

6. Oxidative Stress and Age-Related Changes in T Cells: Is Thalassemia a Model of Accelerated Immune System Aging?, Central European Journal of Immunology (2016)

7. Premature Senescence of T Lymphocytes From Patients With Β-Thalassemia Major, Immunology Letters (2009)

8. Effects of Silymarin on the Proliferation and Glutathione Levels of Peripheral Blood Mononuclear Cells From Β-Thalassemia Major Patients, International Immunopharmacology (2006)

Experts (# of related papers)

View all Related Experts

Nafiseh Esmaeil (8)

Vahid Shaygannejad (4)

Other Related Docs

9. Silymarin Impacts on Immune System As an Immunomodulator: One Key for Many Locks, International Immunopharmacology (2017)

10. Assessment of Pi3k/Akt Signaling Pathway in Activated Human T Lymphocytes in Vitro, Journal of Isfahan Medical School (2012)

11. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)

12. Therapeutic Effects of Deferoxamine and Silymarin Versus Deferoxamine Alone in Β-Thalassemia Major Based on Findings of Liver Mri, Journal of Research in Medical Sciences (2012)

13. The Effects of Silymarin Consumption on Inflammation and Oxidative Stress in Adults: A Systematic Review and Meta-Analysis, Inflammopharmacology (2024)

14. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients, Inflammation (2019)

15. Silymarin Inhibits Cell Cycle Progression and Mtor Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases, Basic and Clinical Pharmacology and Toxicology (2013)

16. Optimization of Human Th17 Cell Differentiation in Vitro: Evaluating Different Polarizing Factors, In Vitro Cellular and Developmental Biology - Animal (2011)

17. Immunosuppressive Effect of Silymarin on Mitogen-Activated Protein Kinase Signalling Pathway: The Impact on T Cell Proliferation and Cytokine Production, Basic and Clinical Pharmacology and Toxicology (2013)

18. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)

19. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, in Patients With Β-Thalassemia Major, Hemoglobin (2013)

20. Silymarin Suppress Cd4+ T Cell Activation and Proliferation: Effects on Nf-Κb Activity and Il-2 Production, Pharmacological Research (2010)

21. Hypercoagulopathy and Serum “Natural Antithrombotic Factors” in Beta-Thalassemia Major, Journal of Isfahan Medical School (2008)

22. Evaluation of Iron Status by Serum Ferritin Level in Iranian Carriers of Beta Thalassemia Minor, International Journal for Vitamin and Nutrition Research (2008)

23. The Effect of Silymarin on the Expression of Chemokine Receptors in T Helper 1 (Th1) Cells, Journal of Isfahan Medical School (2014)

24. Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (Ms) Patients in Vitro, Inflammation (2019)

25. The Effect of Silymarin on the Proliferating of the Activated Human T Cells in Vitro, Journal of Isfahan Medical School (2014)

26. The Effects of Silymarin Supplementation on Metabolic Status and Oxidative Stress in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Clinical Trials, Complementary Therapies in Medicine (2018)

27. Association of Body Mass Index and Serum Ferritin Level in Pediatrics With Beta-Thalassemia Major Disease, Iranian Journal of Pediatric Hematology and Oncology (2022)

Style	Citing Format
MLA	Balouchi S, et al.. "Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy." Immunopharmacology and Immunotoxicology, vol. 36, no. 4, 2014, pp. 271-274.
APA	Balouchi S, Gharagozloo M, Esmaeil N, Mirmoghtadaei M, Moayedi B (2014). Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy. Immunopharmacology and Immunotoxicology, 36(4), 271-274.
Chicago	Balouchi S, Gharagozloo M, Esmaeil N, Mirmoghtadaei M, Moayedi B. "Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy." Immunopharmacology and Immunotoxicology 36, no. 4 (2014): 271-274.
Harvard	Balouchi S et al. (2014) 'Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy', Immunopharmacology and Immunotoxicology, 36(4), pp. 271-274.
Vancouver	Balouchi S, Gharagozloo M, Esmaeil N, Mirmoghtadaei M, Moayedi B. Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy. Immunopharmacology and Immunotoxicology. 2014;36(4):271-274.
BibTex	@article{ author = {Balouchi S and Gharagozloo M and Esmaeil N and Mirmoghtadaei M and Moayedi B}, title = {Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy}, journal = {Immunopharmacology and Immunotoxicology}, volume = {36}, number = {4}, pages = {271-274}, year = {2014} }
RIS	TY - JOUR AU - Balouchi S AU - Gharagozloo M AU - Esmaeil N AU - Mirmoghtadaei M AU - Moayedi B TI - Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy JO - Immunopharmacology and Immunotoxicology VL - 36 IS - 4 SP - 271 EP - 274 PY - 2014 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract